

LIST OF FIGURES

Figure No.	Figure Caption	Pg. No.
Fig. 2-1	Estimates of Dementia prevalence worldwide, adapted from 'World Alzheimer Report-2015'	14
Fig. 3-1	UV Absorption Spectra of VPN in (A) A2M8 and (B) ACN	58
Fig. 3-2	Calibration curves of VPN at 0 h and after 24 h in (A) A2M8 and (B) ACN	59
Fig. 3-3	Absorption spectra to demonstrate specificity of analytical methods for (A) ultradeformable liposomes and (B) polymeric nanoparticles formulations	61
Fig. 3-4	Typical HPLC chromatograms of (A) 0.5 ppm VPN by method-1 and (B) 0.1 ppm VPN by method-2	62
Fig. 3-5	Calibration curves of VPN at 0 h and after 24 h by HPLC (A) method-1 and (B) method-2	63
Fig. 3-6	Typical HPLC chromatograms of 0.5 ppm NPT by (A) method-1 and (B) method-2	66
Fig. 3-7	Calibration curves of NPT at 0 h and after 24 h by HPLC (A) method-1 and (B) method-2	67
Fig. 4-1	UV absorption spectrum of Vinpocetine in 96% Ethanol	78
Fig. 4-2	FT-IR spectrum of Vinpocetine in KBr pellet	78
Fig. 4-3	DSC thermogram of Vinpocetine	79
Fig. 4-4	UV absorption spectrum of Noopept in 95% Ethanol	80
Fig. 4-5	FT-IR spectrum of Noopept in KBr pellet	80
Fig. 4-6	DSC thermogram of Noopept	81
Fig. 4-7	DSC thermograms of A) Vinpocetine; B) Sodium deoxycholate; C) Phospholipon 90H and D) their mixture	82
Fig. 4-8	DSC thermograms of A) Vinpocetine; B) Poloxamer 188; C) Poly lactic-glycolic acid and D) their mixture	82
Fig. 4-9	DSC thermograms of A) Noopept; B) Sodium deoxycholate; C) Phospholipon 90H and D) their mixture	83
Fig. 4-10	DSC thermograms of A) Noopept; B) Poloxamer 188; C) Poly lactic-glycolic acid and D) their mixture	83
Fig. 5A-1	Ishikawa diagram showing probable variables that may influence the CQA	91
Fig. 5A-2	Pareto and Normal plots for A. Vesicular size and B. Drug entrapment	95
Fig. 5A-3	Main effect plots for A. Vesicular size and B. Drug entrapment	95
Fig. 5A-4	Residual plots for vesicle size	101
Fig. 5A-5	Residual plots for drug entrapment	102
Fig. 5A-6	Main effect plots of reduced model for A. vesicular size and B. drug entrapment	102
Fig. 5A-7	Contour and response surface plots of reduced model for vesicular size	103
Fig. 5A-8	Contour and response surface plots of reduced model for drug entrapment	104

Fig. 5A-9	Overlay contour plots of reduced quadratic model showing design space	105
Fig. 5A-10	Optimization solution ramp for defined desirability criteria	106
Fig. 5A-11	A) Contour and B) Response surface plot of composite desirability for both CQA	106
Fig. 5A-12	Transmission electron microscopic images showing (A) multi-lamellae and (B) surface of optimized VPN UDL	108
Fig. 5A-13	Size distribution graph of optimized VPN UDL	109
Fig. 5A-14	Zeta potential graph of optimized VPN UDL	109
Fig. 5A-15	Cumulative percent of VPN released in vitro versus time curve for UDL	110
Fig. 5B-1	Ishikawa diagram showing probable variables that may influence the CQA	119
Fig. 5B-2	Pareto and Normal plots for A. Vesicular size and B. Drug entrapment	123
Fig. 5B-3	Main effect plots for A. Vesicular size and B. Drug entrapment	124
Fig. 5B-4	Residual plots for vesicle size	130
Fig. 5B-5	Residual plots for drug entrapment	131
Fig. 5B-6	Main effect plots of reduced model for A. vesicular size and B. drug entrapment	132
Fig. 5B-7	Contour and response surface plots of reduced model for vesicular size	133
Fig. 5B-8	Contour and response surface plots of reduced model for drug entrapment	134
Fig. 5B-9	Overlay contour plots of reduced quadratic model showing design space	135
Fig. 5B-10	Optimization solution ramp for defined desirability criteria	136
Fig. 5B-11	A) Contour and B) Response surface plot of composite desirability for both CQA	136
Fig. 5B-12	Transmission electron microscopic images showing (A) multi-lamellae and (B) surface of optimized NPT UDL	138
Fig. 5B-13	Size distribution graph of optimized NPT UDL	139
Fig. 5B-14	Zeta potential graph of optimized NPT UDL	139
Fig. 5B-15	Cumulative percent of NPT released in vitro versus time curve for UDL	140
Fig. 6A-1	Ishikawa diagram showing probable variables that may influence the CQA	149
Fig. 6A-2	Pareto and Normal plots for A. Particle size, B. Drug entrapment and C. Drug loading	154
Fig. 6A-3	Main effect plots for A. Particle size, B. Drug entrapment and C. Drug loading	155
Fig. 6A-4	Residual plots for all three CQA	163
Fig. 6A-5	Main effect plots of reduced quadratic model for A. particle size, B. drug entrapment and C. drug loading	164
Fig. 6A-6	Contour plots of reduced quadratic model for A. particle size, B. drug entrapment and C. drug loading	165

Fig. 6A-7	Response surface plots of reduced quadratic model for A. particle size, B. drug entrapment and C. drug loading	165
Fig. 6A-8	Overlaid contour plots of reduced quadratic model with higher and lower range of all three CQA showing design space	166
Fig. 6A-9	Response optimizer plot showing individual and composite desirability of predicted optimum levels	167
Fig. 6A-10	Transmission electron microscopic image of optimized VPN PNP	168
Fig. 6A-11	Size distribution graph of optimized VPN PNP	169
Fig. 6A-12	Zeta potential graph of optimized VPN PNP	169
Fig. 6A-13	Cumulative percent of VPN released in vitro versus time curve for PNP	170
Fig. 6B-1	Ishikawa diagram showing probable variables that may influence the CQA	179
Fig. 6B-2	Pareto and Normal plots for A. Particle size, B. Drug entrapment and C. Drug loading	183
Fig. 6B-3	Main effect plots for A. Particle size, B. Drug entrapment and C. Drug loading	184
Fig. 6B-4	Residual plots for all three CQA	192
Fig. 6B-5	Main effect plots of reduced quadratic model for A. particle size, B. drug entrapment and C. drug loading	193
Fig. 6B-6	Contour plots of reduced quadratic model for A. particle size, B. drug entrapment and C. drug loading	194
Fig. 6B-7	Response surface plots of reduced quadratic model for A. particle size, B. drug entrapment and C. drug loading	194
Fig. 6B-8	Overlaid contour plots of reduced quadratic model with higher and lower range of all three CQA showing design space	195
Fig. 6B-9	Response optimizer plot showing individual and composite desirability of predicted optimum levels	196
Fig. 6B-10	Transmission electron microscopic image of optimized NPT PNP	198
Fig. 6B-11	Size distribution graph of optimized NPT PNP	198
Fig. 6B-12	Zeta potential graph of optimized NPT PNP	199
Fig. 6B-13	Cumulative percent of NPT released in vitro versus time curve for PNP	200
Fig. 7-1	i) Dermastamp L4001 with 36 titanium microneedles of 1.5 mm length; ii) Dermastamp dipped in PDMS to create micromolds; iii) Photograph of PDMS micromold; iv) Microscopic images of PDMS micromold showing microneedle cavities (front and top view).	210
Fig. 7-2	Ishikawa diagram showing probable variables that may influence the CQA	212
Fig. 7-3	Residual plots for axial needle fracture force	217
Fig. 7-4	Main effect plots for ANFF	217
Fig. 7-5	Contour and response surface plots for axial needle fracture force	218
Fig. 7-6	A) Contour and B) Response surface plot of composite desirability for ANFF	219

Fig. 7-7	Photograph of Microneedles A) top, B) side view and C) its patch.	221
Fig. 7-8	SEM images of fast dissolving Microneedles A) top & B) side view	221
Fig. 7-9	A) Load versus time graph for ANFF measurement; B) Trypan blue stained pores on MNP treated pig ear skin	222
Fig. 7-10	Pig ear skin sections showing open pores till 24 hours under occlusive condition A) at 4X and B) at 10X magnification	223
Fig. 7-11	Optical microscopic images of A) VPN UDL, B) VPN PNP, C) NPT UDL and D) NPT PNP loaded fast dissolving microneedles	224
Fig. 7-12	Load versus time curve showing ANFF for microneedle patches of A) VPN UDL, B) VPN PNP, C) NPT UDL and D) NPT PNP.	225
Fig. 7-13	TEM images of A) VPN UDL, B) NPT UDL, C) VPN PNP and D) NPT PNP after re-dispersion from their respective MNP	227
Fig. 7-14	Cumulative percent drug released in vitro versus time curve for all four nanocarriers loaded MNP	228
Fig. 8-1	VPN distribution profile from its formulations after 24 h of permeation experiment on full thickness pig ear skin	238
Fig. 8-2	NPT distribution profile from its formulations after 24 h of permeation experiment on full thickness pig ear skin	240
Fig. 8-3	Fluorescence microscopic images of pig ear skin sections after 12h of treatment with A) FITC suspension, B) FITC MNP, C) FITC UDL _{VPN} , D) FITC UDL MNP _{VPN} , E) FITC PNP _{VPN} , F) FITC PNP MNP _{VPN}	241
Fig. 8-4	Fluorescence microscopic images of pig ear skin sections after 12h of treatment with A) FITC suspension, B) FITC MNP, C) FITC UDL _{NPT} , D) FITC UDL MNP _{NPT} , E) FITC PNP _{NPT} , F) FITC PNP MNP _{NPT}	242
Fig. 8-5	Percent viability of HaCaT cells after exposure to VPN formulations or appropriate controls	243
Fig. 8-6	Percent viability of HaCaT cells after exposure to NPT formulations or appropriate controls	244
Fig. 9-1	Training schedule for each rat	252
Fig. 9-2	Plasma VPN concentration vs Time profile of various dosage forms in Sprague Dawley rats	254
Fig. 9-3	Plasma NPT concentration vs Time profile of various dosage forms in Sprague Dawley rats	256
Fig. 9-4	Mean escape latency time (in second) during training sessions	258
Fig. 9-5	Graphical representation of mean escape latencies for PD study of VPN	259
Fig. 9-6	Graphical representation of mean escape latencies for PD study of NPT	260